Introduction to degenerative processes in osteoarthritis
========================================================

Osteoarthritis is the most common form of arthritis and the most common indication for total hip and total knee replacement. It is a progressive joint disease associated with aging. Many elderly people have some degree of osteoarthritis. It may be found in the knees, hips, or other joints. Risk factors for the development and/or progression of osteoarthritis identified in epidemiological studies can be broadly divided into systemic factors that increase the susceptibility to the disease and local biomechanical factors that influence the development of osteoarthritis at the particular joint. It is estimated that costs associated with osteoarthritis exceed 2% of the gross national product in developed countries. In this context, the clear need for a better understanding of the disease process has rendered undeniable the importance of finding drugs that can reduce or stop its progression.

The progression of the structural changes that occur during the course of the disease is related to a number of complex pathways and mechanisms, among which the excess production of proteolytic enzymes that can degrade the cartilage matrix and soft tissues surrounding the joint is believed to be of particular importance ([@b23-cia-2-73]). The degradation of the osteoarthritis cartilage matrix has been shown to be related to the excess synthesis of a large number of proteases and, more particularly, to that of the matrix metalloproteinases (MMPs) and thioldependent families. Among the MMPs, two collagenases, MMP-1 and MMP-13, have been the subject of extensive investigation and were found likely to be the primary enzymes involved in the breakdown of type II collagen in osteoarthritis cartilage ([@b25-cia-2-73]). Cathepsin K, a thiol-dependent enzyme that works preferentially under acidic pH conditions, has also been demonstrated to be synthesized by osteoarthritis chondrocytes and is likewise believed to play an important role in the breakdown of the osteoarthritis cartilage collagen network ([@b17-cia-2-73]) as well as the aggrecans, and thus likely involved in degrading the cartilage extracellular matrix. The mechanisms involved in the degradation of the aggrecans in osteoarthritis cartilage have also been extensively explored and studied, which has led to the identification of a number of proteolytic enzymes that can specifically degrade aggrecans ([@b27-cia-2-73]). Comprehensive investigation has indicated that the MMPs, including MMP-13, aggrecanase-1 (a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS-4), and aggrecanase-2 (ADAMTS-5), are the proteolytic enzymes that seem the most likely to be involved in the degradation of aggrecans in osteoarthritis cartilage ([@b18-cia-2-73]; [@b7-cia-2-73]).

Recent studies have revealed new and interesting information regarding the role played by eicosanoids in the pathophysiology of arthritic diseases, including osteoarthritis ([@b11-cia-2-73]; [@b36-cia-2-73]; [@b10-cia-2-73]; [@b15-cia-2-73]; [@b24-cia-2-73], 2004). For instance, leukotriene-B4 (LTB4) has proven to be an important regulating factor in the synthesis of IL-1β by osteoarthritis synovium ([@b37-cia-2-73]; [@b15-cia-2-73]; [@b12-cia-2-73]). Both in vitro and in vivo studies have demonstrated that the excess production of IL-1β in osteoarthritis tissue is a key factor in its destruction and in the progression of the disease itself ([@b34-cia-2-73]; [@b23-cia-2-73]). The endogenous production of LTB4 in osteoarthritis synovium is a crucial element in the upregulation of IL-1β synthesis in this tissue ([@b12-cia-2-73]). The synthesis of LTB4, and subsequently of IL-1β, can be significantly increased by nonsteroidal anti-inflammatory drugs (NSAIDs) ([@b29-cia-2-73]; [@b22-cia-2-73]). It has been hypothesized that this could be related to a 'shunt' of the arachidonic acid cascade from the cyclooxygenase (COX) to the lipoxygenase (LOX) pathway ([@b24-cia-2-73]). These findings could help explain how some NSAIDs accelerate the progression of clinical osteoarthritis ([@b14-cia-2-73]). A recent study has demonstrated that, in in vivo experimental osteoarthritis, licofelone, a drug that can inhibit both the COX and 5-LOX pathways, was capable of reducing the development of osteoarthritis structural changes while simultaneously reducing the synthesis of LTB4 and IL-1β by the osteoarthritis synovium ([@b15-cia-2-73]). These findings are in strong support of the in situ role played by LTB4 in the structural changes that occur in osteoarthritis.

Review of pharmacology, mode of action, and pharmacokinetics of licofelone
==========================================================================

Arachidonic acid (C20:4), a ω-6 essential fatty acid, is metabolized by several enzymes, in different tissues. After the cleavage from membrane phospholipids, arachidonic acid generates a lot of compounds with a wide range of clinical effects involved in inflammation. It is very complicated to quantitatively determine the final effect of arachidonic acid metabolism resulting from the sum of different actions of its metabolites. In fact, just to calculate COX and LOX products' global effect, we have to consider more than 25 active substances, each with two to five different actions, having different cellular or extracellular tissue and organ targets, depending on their different baseline and under-stimulus production rate ([Figure 1](#f1-cia-2-73){ref-type="fig"}) ([@b3-cia-2-73]). A detailed description of the arachidonic acid metabolism and the function of its metabolites is not part of the scope of this overview; therefore, the different effect of inhibitory drugs on COX-1, COX-2, and/or LOX appears to be clinically relevant ([Figure 2](#f2-cia-2-73){ref-type="fig"}). The anti-inflammatory mechanism of action of NSAIDs is attributed to the inhibition of COX, and, consequently, the conversion of arachidonic acid into prostaglandins. It is hypothesized that the main undesirable side-effects of NSAIDs are due to the inhibition of COX-1 (constitutive isoform), whereas the beneficial effects are related to the inhibition of COX-2 (inducible isoform). This is why selective COX-2 inhibitors seem to be safer with regard to gastric damage ([@b47-cia-2-73]). Arachidonic acid can also be converted to LTs by the action of 5-LOX. LT-C4, LT-D4 and LT-E4 are potent bronchoconstrictors, whereas LT-B4 is chemotactic for leukocytes and plays an important role in the development of gastrointestinal ulcers by contributing to the inflammatory process. Thus, developing dual inhibitor compounds that will simultaneously inhibit COX and 5-LOX could enhance their individual anti-inflammatory effects and reduce the undesirable side-effects associated with NSAIDs, especially of the gastrointestinal (GI) tract ([@b9-cia-2-73]). Moreover, lipoxins are also LOX-derived prostanoids, though their biological actions differ dramatically from LTs. In fact, lipoxins inhibit bronchoconstriction and carry local anti-inflammatory signals. Therefore, inhibitors of 5-LOX/COX which do not block the 12-LOX and 15-LOX pathways should allow unbridled synthesis of lipoxins to resolve inflammation and attenuate any remaining LT effect ([@b42-cia-2-73]). Several chemically distinct compounds are in different phases of preclinical or clinical development: BF-389, RWJ 63556, PGV 20229, BW755C, CI-986, SK&F 105809, FPL 62064, PD 127443, PD 137968, L-652,343, CBS-1108, licofelone (ML3000), but none already marketed ([@b6-cia-2-73]). The first one currently involved in phase III clinical trials is licofelone (ML3000) (\[2,2-dimethy l-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl\]-acetic acid) ([@b39-cia-2-73]).

Preclinical data
----------------

Preclinical data show that licofelone has anti-inflammatory, analgesic, antipyretic, and antiplatelet ([@b20-cia-2-73], [@b19-cia-2-73]; [@b1-cia-2-73]; [@b41-cia-2-73]; [@b43-cia-2-73]) activities. Licofelone has been shown in vitro to suppress the polymorphonuclear (PMN) leukocyteplatelet transcellular metabolism of arachidonic acid, prevent PMN aggregation and activation, and reduce PMN and platelet adhesion ([@b40-cia-2-73]), all of which are relevant to the pathogenesis of inflammation.

General toxicological studies in animals have also demonstrated that licofelone is devoid of deleterious effects on the autonomic nervous system, CNS, and cardiovascular system, being safe at doses far above pharmacologically active doses ([@b2-cia-2-73]). In addition, licofelone has no genotoxic potential ([@b13-cia-2-73]).

Further studies in animals have demonstrated that licofelone has a lower ulcerogenic potential than aspirin, indometacin, and diclofenac ([@b46-cia-2-73]).

Interestingly, in contrast to COX-2 inhibitors, licofelone does not exacerbate gastric mucosal damage, even in aspirin-treated rats, thus creating the possibility of concomitant treatment with aspirin and licofelone in osteoarthritic patients with cardiovascular risk who require long-term aspirin therapy ([@b8-cia-2-73]). A clinical study confirmed that the co-administration of low-dose, enteric-coated aspirin and licofelone did not produce a clinically relevant increase in the occurrence of gastrointestinal ulcers ([@b5-cia-2-73]). However, the long-term effect of this association on cardiovascular outcomes has yet to be determined.

Licofelone also appears to have specific anti-arthritic activity in animals. In a rat experimental model of adjuvant arthritis, licofelone given at doses ranging between 20 mg/kg and 80 mg/kg for 26 days significantly reduced erythema and oedema, as well as arthritis-associated splenomegaly ([@b10-cia-2-73]). Histological examination of the joints also revealed reduced synovial cell proliferation and bone/cartilage erosions, suggesting selective activity of the drug on synovial fibroblasts.

Prevention of cartilage degradation by licofelone has also been observed in an experimental dog model of osteoarthrosis in which the anterior cruciate ligament of the stifle joint was surgically removed ([@b15-cia-2-73]; [@b26-cia-2-73]). Administration of licofelone 2.5--5 mg/kg/day for 8 weeks significantly reduced the size and grade of the cartilage lesions. In the low-dose group (2.5 mg/kg/day), the size of lesions was lowered by 39% on femoral condyles and by 45% on tibial plateaus in comparison with placebo-treated animals, whereas in the high-dose group (5 mg/kg/day) the reductions were 64% and 54%, respectively. Moreover, while the synovium from placebo-treated dogs was hypertrophic and evidently discolored, in dogs treated with licofelone the synovium was thinner and the discoloration was less intense. Anti-arthritic activity was accompanied not only by a combined reduction in the synovial synthesis of PGE2 and LTB4, but also by a reduction in two major catabolic factors involved in cartilage degradation, namely interleukin (IL)-1β and collagenase 1. Only intra-articular injections of corticosteroid ([@b32-cia-2-73]) and NSAIDs such as tenidap ([@b44-cia-2-73]) have produced similar results, with reduced synthesis of IL-1β and IL-6; intra-articular injections of the NSAIDs naproxen ([@b44-cia-2-73]), carprofen ([@b33-cia-2-73]), and tiaprofenic acid ([@b35-cia-2-73]) did not produce these effects. Furthermore, under the same experimental conditions, aspirin may actually accelerate cartilage destruction ([@b28-cia-2-73]). Since LTB4 plays an important role in the regulation of the synthesis of IL-1β, IL-6, and IL-8 in the synovial membrane ([@b29-cia-2-73]), the anti-arthritic activity of licofelone may be mediated primarily through inhibition of LTB4 synthesis. Indeed, selective inhibition of 5-LOX and LTB4 synthesis is associated with a reduced production of these cytokines in vitro ([@b37-cia-2-73]).

All therapeutic potentialities of licofelone, studied by international literature, are resumed in [Table 1](#t1-cia-2-73){ref-type="table"}.

Efficacy studies and safety of licofelone in humans
===================================================

First studies in humans indicate a very good gastric safety, a positive effect on bone cell remodelling and on osteoarthritis, as well. In an endoscopic study, 121 subjects with normal gastric and duodenal mucosa were randomly assigned a 4-week treatment with licofelone 200 mg twice daily (bid) or 400 mg bid, placebo or naproxen 500 mg bid. Groups were matched with respect to *Helicobacter pylori* status (19% positive). After 4 weeks the mucosa of the stomach and duodenum was endoscopically evaluated. Mean ± standard deviation gastric score with both 200 mg and 400 mg bid of licofelone were similar to placebo and statistically less than with naproxen: 0.13 ± 0.57 (200), 0.14 ± 0.45 (400), 0.20 ± 0.66 (placebo), 1.47 ± 1.31 (naproxen), respectively. The gastric mucosa was completely normal in 93%, 89%, 90%, and 37% of subjects, respectively.

Duodenal scores were worst with naproxen but not significantly different among groups in the given sample size: 0.00, 0.11 ± 0.57, 0.00, 0.20 ± 0.81. The results were qualitatively similar in *H. pylori* positive and negative subgroups. Ulcer with unequivocal depth occurred significantly more frequently in naproxen-treated subjects (6/30 = 20%; five gastric ulcers, one duodenal ulcer) than in other groups; no ulcer were present in either licofelone group or the placebo group ([@b16-cia-2-73]). In another clinical study, 148 patients with knee osteoarthritis were treated for 12 weeks with licofelone 200 mg bid or naproxen 500 mg bid. Efficacy was evaluated using the Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index. Responders were defined to show a 30% improvement versus baseline. With licofelone, the mean WOMAC index was improved by 23.3 mm and with naproxen there was an improvement by 21.5 mm. For the WOMAC index, 69.4% of licofelone-treated patients were responders (68.4% with naproxen). GI adverse events were reported by 13.9% (licofelone) and by 26.3% (naproxen) of patients ([@b39-cia-2-73]). A 52-week trial was performed to determine the long-term tolerability and efficacy of licofelone compared with naproxen. This trial demonstrated that licofelone was at least as effective as naproxen in osteoarthritis treatment ([@b4-cia-2-73]). Patients with symptomatic osteoarthritis of the knee (as defined by American College of Rheumatology guidelines), who had discontinued NSAID therapy 3--14 days prior to the baseline visit, were randomized to receive licofelone 100 mg bid, licofelone 200 mg bid or naproxen 500 mg bid in this multicentre, double-blind, phase III trial. Licofelone treatment was associated with a dose-dependent improvement in WOMAC pain scores from baseline. The efficacy of licofelone 200 mg was similar to that of naproxen during the study. Mean changes in WOMAC pain scores, from a mean baseline value of 63.9 mm, were 27.1 mm, 30.2 mm, and 27.7 mm for licofelone 100 mg, licofelone 200 mg and naproxen, respectively. Adverse event rates again confirmed the superior tolerability of licofelone compared with naproxen, with patients in the 100 mg and 200 mg licofelone treatment groups experiencing fewer events than those in the naproxen group (59.2%, 56.3%, and 66.7%, respectively). In particular, lower frequencies of peripheral oedema and aggravated hypertension were recorded for licofelone compared with naproxen. Long-term licofelone therapy did not result in any clinically relevant variations in laboratory parameters or vital signs.

Licofelone 200 mg twice daily was also compared with celecoxib 200 mg once daily in a 12-week clinical study of patients with symptomatic osteoarthritis of the knee ([@b31-cia-2-73]). Licofelone was as effective as celecoxib, but showed better tolerability with a lower incidence of adverse events.

Conclusion: place in therapy
============================

LOX/COX inhibitors equally block both the COX-1 and COX-2, and the 5-LOX metabolic pathways, inhibiting the formation of prostaglandins, thromboxanes, and LTs ([@b39-cia-2-73]). The main reason for the search for a new class of anti-inflammatory agents is the need for safer drugs, because traditional and more recent ones have failed to show a high safety profile, especially in "frail" patients, as the elderly.

The pharmacological profile of LOX/COX inhibitors is quite similar to that of glucocorticoids drugs, which inhibit PLA2 and thereby prevent arachidonic metabolism by both COX and 5-LOX, without the severe adverse events on the endocrine system and on the metabolism intermediates of PLA2, normally associated with the use of these steroid drugs ([@b30-cia-2-73]). What is especially interesting is that these drugs seem to positively affect the cartilage metabolism thus contrasting the degenerative process of osteoarthritis ([@b15-cia-2-73]), while significantly reducing pain and pain-related disability. At present time, this seems to be one of the more interesting paths for the future development of potent-and-safe drugs that can reduce damage derived from inappropriate and widespread use of conventional NSAIDs. From this point of view, the new class of the LOX/COX inhibitors present several beneficial and promising therapeutic effects that could be very important in the elderly ([@b45-cia-2-73]), and mainly: potentially higher anti-inflammatory and anti-pain efficacy;positive action on the bronchial tract (inhibition of bronchoconstriction);reduced adverse effects on the upper GI tract, even with chronic treatment;reduced interaction with ASA.

Moreover, dual COX/LOX inhibition could reduce the incidence or the progression of many cancers, as assessed by many preclinical studies ([@b21-cia-2-73]). The main limitations of these conclusions are related to the fact that we have yet a lack of published data about clinical effectiveness and safety of COX/LOX dual inhibitors (the most part of those reported in this review have been found in posters presented at international meetings) and that only licofelone has reached the phase III study level. First results on licofelone use in humans are very encouraging (Reginster et al 2003), but larger clinical trials need to define its efficacy and safety and the possibilities of widespread use in the elderly. In fact, clinical studies need to be done, aimed at confirming these clinical effects and safety profile of LOX/COX inhibitors in the elderly. This last point is very important, since elderly will be the first class of NSAIDs consumers in the future. Therefore, it is necessary to adequately study these drugs, especially in the pathological conditions of the fragile elderly patient or the pluripathologic patient (with a polipharmacotherapy), avoiding publication bias caused by missing data.

![Actions of eicosanoids: from the enzymes to the main effects through the superfamily of metabolic products (simplified pathway) Copyright © 2002. Modified with permission from [@b3-cia-2-73]. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. *Curr Med Chem,* 9:1033--43.\
**Abbreviations:** COX, cyclooxygenase; LOX, lipoxygenase.](cia-2-73f1){#f1-cia-2-73}

![Effect of COX-1 and COX-2 inhibition on mechanisms involved in CHD pathogenesis Copyright © 2000. Modified with permission from Whelton 2000.\
**Abbreviations:** COX, cyclooxygenase; LOX, lipoxygenase; PGI, prostaglandin; TxA, thromboxane A.](cia-2-73f2){#f2-cia-2-73}
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Therapeutic potentialities of licofelone

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Effects of licofelone from preclinical data Anti-inflammatoryAnalgesicAntipyreticAntiplatelet
  Effects in vitro Suppression of the PMN leukocyteplatelet transcellularmetabolism of arachidonic acidPrevention of PMN aggregation and activationReduction of PMN and platelet adhesion
  Effects in animal models Reduction of erythema and oedema in osteoarthritisReduction of synovial cell proliferationReduction of bone/cartilage erosion
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** PMN, polymorphonuclear.
